Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)

@inproceedings{Emery2010ImpactOT,
  title={Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)},
  author={Paul Emery and Patrick Durez and Maxine Dougados and Clarence William Legerton and J-C Becker and George Vratsanos and Harry K. Genant and Charles G. Peterfy and Priyam Mitra and Sandra Overfield and Keqin Qi and Ren{\'e} Westhovens},
  booktitle={Annals of the rheumatic diseases},
  year={2010}
}
BACKGROUND Several agents provide treatment for established rheumatoid arthritis (RA), but a crucial therapeutic goal is to delay/prevent progression of undifferentiated arthritis (UA) or very early RA. OBJECTIVE To determine the impact of T-cell costimulation modulation in patients with UA or very early RA. METHODS In this double-blind, phase II, placebocontrolled, 2-year study, anti-cyclic citrullinated peptide (CCP)2-positive patients with UA (not fulfilling the ACR criteria for RA) and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 103 extracted citations

Rheumatoid arthritis

Nature Reviews Disease Primers • 2018

References

Publications referenced by this paper.
Showing 1-10 of 58 references

Similar Papers

Loading similar papers…